Public list: Pharma Startups (6570) Cancer Therapeutics (1180)
Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the frontier of antibody discovery by creating well-char...Show all
Company (Acquired)
Phone: +45 4526 5050
Pederstrupvej 93
Ballerup, DK-2750
Denmark
Total Funding | Date of Last Funding | |
---|---|---|
Symphogen | $364.2M | Apr 3, 2020 |
Humanetics Corporation | $0.6M | Jul 23, 2020 |
PharmAthene | $61.2M | Mar 14, 2005 |
See all 19 competitors |
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Anti-met antibodies and compositions | Sep 15, 2015 | Oct 22, 2019 | Patent |
Pan-her antibody composition | Nov 28, 2016 | Mar 05, 2019 | Patent |
Humanized pan-her antibody compositions | Nov 14, 2016 | Aug 28, 2018 | Patent |
Humanized pan-her antibody compositions | May 02, 2013 | Dec 27, 2016 | Patent |
Anti-her3 antibodies and compositions | Oct 31, 2011 | Dec 22, 2015 | Patent |